期刊
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
卷 431, 期 4, 页码 647-651出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2013.01.041
关键词
Nitric oxide; Cancer therapy; Adjuvant therapy; Pro-drugs; Cell signaling
资金
- National Science Foundation [1060548]
- CVMBS College Council
- Flint Animal Cancer Center
- Department of Defense Congressionally Directed Research Program [DOD-CDMRP W81XWH-11-2-0113]
- Direct For Education and Human Resources
- Division Of Undergraduate Education [1060548] Funding Source: National Science Foundation
Tumor resistance to cytotoxic therapeutics coupled with dose-limiting toxicity is a serious hurdle in the field of medical oncology. In the face of this obstacle, nitric oxide has emerged as a powerful adjuvant for the hypersensitization of tumors to more traditional chemo- and radio-therapeutics. Furthermore, emerging evidence indicates that nitric oxide donors have the potential to function independently in the clinical management of cancer. Herein, we discuss the role of nitric oxide in cancer and the potential for nitric oxide donors to support conventional therapeutics. (C) 2013 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据